Wikis > Neurology > Hyperkinetic movement disorders/dyskinesias > Restless Legs Syndrome > Restless Legs Syndrome Clinical Trials
For the purposes of transparency it is generally required that all clinical trials be registered in advance.
List of Restless Legs Syndrome Clinical Trials:
| Trial | About | Link | Keywords | Outcome |
|---|---|---|---|---|
| Infra-slow Oscillations During Sleep (SleepD-ISO) | In this study the investigators plan to systematically characterise infra-slow EEG oscillations during sleep, explore their relationship to the microstructure of sleep, and investigate its role in the physiology and pathophysiology of sleep by co-registration of Full band EEG with polysomnography during wake and sleep in healthy subjects, after sleep deprivation, and in patients with restless legs syndrome/periodic leg movements during sleep (RLS/PLMS). | Link | Periodic Limb Movements During Sleep; Sleep | |
| Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome (CES in RLS) | The purpose of this study is to assess the feasibility and effectiveness of Cranial Electrical Stimulation (CES) therapy in treating symptoms of Restless Legs Syndrome (RLS). Participants will be randomly assigned to one of three groups, a usual care (control group), an active CES device group and a sham (inactive) CES device group. Those who are enrolled in one of the device groups will not know which type of device they have (blinding). Those enrolled in the usual care group and sham groups will ultimately have the option to use the active device after they complete the study. Study length for participants is 8 weeks. | Link | ||
| Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome | The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome. | Link | Gabapentin | |
| An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS | The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome (RLS) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS. | Link | Gabapentin |
Related Topics:
RESTIFFIC™ Foot Wrap | Growing Pains and Restless Legs Syndrome in Children | International RLS Study Group Rating Scale | Restless Legs Syndrome News
Restless Legs Syndrome Books:
Related Topics:
Restless Legs Syndrome | RESTIFFIC™ Foot Wrap | Growing Pains and Restless Legs Syndrome in Children | International RLS Study Group Rating Scale | Restless Legs Syndrome News
Page last updated:
Comments are closed.